December 31, 2018
WELLESLEY, Mass., Dec. 31, 2018 – The rise of immunodeficiency across multiple regions, coupled with new product launches and advancements in existing technologies, are driving growth in the global blood plasma products market, according to BCC Research.
The global blood plasma products market was valued at $25.7 billion in 2018 and is expected to reach $35.5 billion by 2023 at a compound annual growth rate (CAGR) of 6.6% during the forecast period, according to the report “Global Markets for Blood Plasma Products.”
Major players in the market include: CSL Ltd. (CMXHF), Kedrion S.p.A., Grifols SA (GIFOF), Biotest AG (BIO), Shire (SHPGF), Sanquin, China Biologic Products (CBPO) and Octapharma AG, among others.
“In developed regions, the growing number of chronic disease cases has contributed to the demand for blood plasma,” the report notes. “Hospitals, clinics and blood donation centers tend to focus on blood plasma collection by encouraging people to donate plasma, but stringent eligibility rules designed to prevent disease transmission hamper supply.”
Factors Limiting Growth of the Global Blood Plasma Products Market
The increasing employment of recombinant plasma products in therapeutic treatments, the high cost of blood plasma therapies, stringent government regulation and low reimbursement policies are current restraints to the global market for blood plasma products.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Global Markets for Blood Plasma Products( HLC201B )
Publish Date: Dec 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.